Ignite Creation Date:
2025-12-24 @ 4:21 PM
Ignite Modification Date:
2026-01-01 @ 6:58 PM
Study NCT ID:
NCT01142466
Status:
COMPLETED
Last Update Posted:
2014-02-27
First Post:
2010-06-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase IV Study of Rebif ® 44mcg Administered Three Times Per Week by Subcutaneous Injection Compared With no Treatment in the Therapy of Relapsing Multiple Sclerosis After Mitoxantrone
Sponsor:
Merck KGaA, Darmstadt, Germany
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Multiple Sclerosis, Relapsing-Remitting | View |